全球医药原料药/合约研发生产机构市场规模、份额、趋势及成长分析报告（2026-2034）

原料药(API) 的合约开发和生产 (CDMO) 市场预计将从 2025 年的 978.7 亿美元增长到 2034 年的 1904.9 亿美元，2026 年至 2034 年的复合年增长率为 7.68%。

受製药公司外包需求增加的推动，全球原料药（原料药）和合约研发生产机构（CDMO）市场正经历强劲成长。 CDMO在原料药开发、规模化生产和商业化生产方面提供专业知识。药物研发活动的活性化以及对高性价比生产解决方案日益增长的需求正在推动市场扩张。

关键成长要素包括药物分子日益复杂化、生物製药生产规模扩大以及监管合规要求日益严格。製药公司越来越多地与合约研发生产机构（CDMO）合作，以缩短产品上市时间并优化营运成本。此外，对学名药和专科药物生产投资的增加也支撑了市场需求。

随着人们对个人化医疗和高活性原料药的关注度不断提高，市场前景依然乐观。新兴市场生产设施的扩张带来了巨大的成长机会。製程优化和品管方面的持续创新将增强市场竞争力。随着全球医药研发的持续成长，原料药合约研发生产（API CDMO）市场预计将维持长期稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球药品原料药/ CDMO市场：依产品分类

• 市场分析、洞察与预测
• 传统药物原料药（API）
• 高效活性原料药（HP-APIs）
• 抗体药物复合体（ADC）
• 其他的

第五章：全球原料药CDMO市场：依合成方式划分

• 市场分析、洞察与预测
• 合成
• 生物技术

第六章 全球药品原料药CDMO市场：依药物类型划分

• 市场分析、洞察与预测
• 创新的
• 学名药

第七章 全球原料药CDMO市场：依工作流程划分

• 市场分析、洞察与预测
• 临床
• 商业的

第八章 全球医药原料药/ CDMO市场：依应用领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 荷尔蒙药物
• 青光眼
• 心血管疾病
• 糖尿病
• 其他的

第九章 全球医药原料药/ CDMO市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Cambrex Corporation
  • Recipharm AB
  • Thermo Fisher Scientific Inc.（Pantheon）
  • CordenPharma International
  • Samsung Biologics
  • Lonza
  • Catalent Inc
  • Siegfried Holding AG
  • Piramal Pharma Solutions
  • Boehringer Ingelheim International GmbH

The Active Pharmaceutical Ingredient CDMO Market size is expected to reach USD 190.49 Billion in 2034 from USD 97.87 Billion (2025) growing at a CAGR of 7.68% during 2026-2034.

The Global Active Pharmaceutical Ingredient CDMO Market is experiencing strong growth due to increasing outsourcing by pharmaceutical companies. Contract development and manufacturing organizations (CDMOs) provide specialized expertise in API development, scale-up, and commercial production. Rising drug development activities and growing demand for cost-efficient manufacturing solutions are driving market expansion.

Major growth drivers include increasing complexity of drug molecules, expansion of biologics production, and regulatory compliance requirements. Pharmaceutical companies are partnering with CDMOs to accelerate time-to-market and optimize operational costs. Additionally, growing investment in generic and specialty drug manufacturing supports demand.

Future prospects remain positive with rising focus on personalized medicine and high-potency APIs. Expansion of manufacturing facilities in emerging markets offers significant growth opportunities. Continuous innovation in process optimization and quality control will strengthen market competitiveness. As pharmaceutical R&D continues to grow globally, the API CDMO market is expected to maintain steady long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Traditional Active Pharmaceutical Ingredient (Traditional API)
• Highly Potent Active Pharmaceutical Ingredient (HP-API)
• Antibody Drug Conjugate (ADC)
• Others

By Synthesis

• Synthetic
• Biotech

By Drug

• Innovative
• Generics

By Workflow

• Clinical
• Commercial

By Application

• Oncology
• Hormonal
• Glaucoma
• Cardiovascular Disease
• Diabetes
• Others

COMPANIES PROFILED

• Cambrex Corporation, Recipharm AB, Thermo Fisher Scientific Inc Pantheon, CordenPharma International, Samsung Biologics, Lonza, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim International GmbH
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Traditional Active Pharmaceutical Ingredient (Traditional API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antibody Drug Conjugate (ADC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY SYNTHESIS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Synthesis
• 5.2. Synthetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biotech Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY DRUG 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug
• 6.2. Innovative Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Workflow
• 7.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Application
• 8.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Hormonal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product
  • 9.2.2 By Synthesis
  • 9.2.3 By Drug
  • 9.2.4 By Workflow
  • 9.2.5 By Application
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product
  • 9.3.2 By Synthesis
  • 9.3.3 By Drug
  • 9.3.4 By Workflow
  • 9.3.5 By Application
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product
  • 9.4.2 By Synthesis
  • 9.4.3 By Drug
  • 9.4.4 By Workflow
  • 9.4.5 By Application
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product
  • 9.5.2 By Synthesis
  • 9.5.3 By Drug
  • 9.5.4 By Workflow
  • 9.5.5 By Application
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product
  • 9.6.2 By Synthesis
  • 9.6.3 By Drug
  • 9.6.4 By Workflow
  • 9.6.5 By Application
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Cambrex Corporation
  • 11.2.2 Recipharm AB
  • 11.2.3 Thermo Fisher Scientific Inc. (Pantheon)
  • 11.2.4 CordenPharma International
  • 11.2.5 Samsung Biologics
  • 11.2.6 Lonza
  • 11.2.7 Catalent Inc
  • 11.2.8 Siegfried Holding AG
  • 11.2.9 Piramal Pharma Solutions
  • 11.2.10 Boehringer Ingelheim International GmbH